Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  7-hydroxystaurosporine
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-20 of 20 for your search:
Start Over
Combination Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000256600, PMH-PHL-006, NCI-5538, 5538, NCT00045513
Phase II Study of UCN-01 and Fluorouracil in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-02049, NCI-5509, 5509, NCT00045747
UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000339563, PMH-PHL-019, NCI-6402, 6402, NCT00072267
UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 7 and over
Sponsor: NCI
Protocol IDs: 040173, 04-C-0173, NCI-04-C-0173, NCI-6070, 6070, NCT00085319, NCT00082017
7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-03092, 6992, PHL032, N01CM62203, PMH-PHL-032, NCI-6992, NCT00098956
Phase I Study of Continuous-Infusion UCN-01 (a Staurosporine Analogue) in Patients With Refractory Solid Tumors or Lymphoma
Phase: Phase I
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: NCI
Protocol IDs: NCI-95-C-0171N, NCI-T95-0052N, T95-0052
UCN-01 in Treating Patients With Advanced Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: JHOC-J9814, CDR0000066221, U01CA070095, P30CA006973, JHOC-98012305, NCI-T97-0083, NCT00003289
UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CDR0000067252, NCI-99-C-0127, NCI-T99-0022, T99-0022, NCT00019838
Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Phase: Phase I
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: DM99-165, U01CA062461, P30CA016672, MDA-DM-99165, NCI-T99-0100, CDR0000067522, T99-0100, NCT00004263
UCN-01 and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000068274, U01CA062505, P30CA033572, CHNMC-PHI-28, NCI-T99-0065, T99-0065, NCT00006464
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00019, NCI-5582, WUSM-SCC-0102, CDR0000069215, UVACC-SCC-0102, SCC 01-02, 5582, P30CA044579, NCT00031681
UCN-01 and Carboplatin in Treating Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00042, UMGCC 0143, MSGCC-0143, NCI-5533, CDR0000069321, U01CA069854, 5533, NCT00036777
UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02468, DM01-553, U01CA062461, CDR0000069380, MDA-DM-01553, NCI-5510, 5510, NCT00039403
UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CDR0000256599, NCI-02-C-0241, NCI-5694, 5694, NCT00045500
UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000256917, PMH-PHL-005, NCI-5518, 5518, NCT00045175
UCN-01 and Irinotecan in Treating Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: JHOC-J0173, CDR0000257566, U01CA070095, P30CA006973, JHOC-J0173, NCI-5528, 5528, NCT00047242
7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00149, MSGCC-0507, NCI-7311, MSGCC-H-27229-0507, CDR0000465368, GCC 0507, 7311, NCT00301938
UCN-01, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CDR0000069478, NCI-NAVY-01-04, NCI-5535, NCI-02-C-0222, NCT00042861
Start Over